Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

University of Oxford-led ROADMAP project releases public leaflet

The acronym ROADMAP stands for: “Real world Outcomes across the Alzheimer’s Disease spectrum for better care: Multi-modal data Access Platform”.

Phase 1 of ROADMAP began in November 2016 and lasts for two years. October 2017, therefore, marks the halfway point of the project.

In Phase 1 ROADMAP’s goal is to lay the foundation of an EU-wide data sharing space for real-world evidence (RWE) outcomes for better care in Alzheimer's disease.

By the end of October 2018, the ROADMAP consortium, a public private collaboration of 25 partners from Europe, coordinated by the University of Oxford and Novartis, aims to deliver guiding principles and recommendations on integrating available RWE to support healthcare decision making in AD treatment and research.

Read more (Department of Psychiatry website)